Ascletis Pharma Inc. has announced that its Phase III clinical trial for denifanstat (ASC40), a first-in-class, once-daily oral fatty acid synthase (FASN) inhibitor, has met all primary, key secondary, and secondary endpoints for the treatment of moderate to severe acne vulgaris. The randomized, double-blind, placebo-controlled, multicenter trial conducted in China involved 480 patients. Denifanstat demonstrated a statistically significant improvement in treatment outcomes, with a 33.2% treatment success rate and reductions in total, inflammatory, and non-inflammatory lesion counts by 57.4%, 63.5%, and 51.9% respectively, compared to baseline. The trial results indicate that denifanstat was more effective than several FDA-approved acne treatments in placebo-adjusted percent treatment success. The drug maintained a favorable safety and tolerability profile throughout the study. Ascletis plans to submit the treatment for approval by the China National Medical Products Administration (NMPA).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.